|TRIO-US Lilly 13Y-MC-JPBZ
||A phase 2, randomized, multicenter, 3-Arm, open-label study to compare the efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to standard-of-care chemotherapy of physician's choice plus Trastuzumab in women with HR+, HER2+ locally advanced or metastatic breast Cancer
|TRIO-US Novartis LEE011XUS29 Triniti -1
||A phase I/II, single arm, open-label study of Ribociclib in combination with Everolimus + Exemestane in treatment of men and postmenopausal women with HR+, HER2- locally advanced or metastatic breast cancer following progression on DCK 4/6 inhibitor
|Novartis CBYL719C2301 SOLAR-1
||SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment.